119th Congress · introduced in the House · Jul 20, 2026
To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.
Official title from Congress.gov
Latest action (Jul 20, 2026): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
1 citation.
CHATTEM, INC D/B/A OPELLA · lobbying firm or registrant: CHATTEM, INC D/B/A OPELLA
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 6, 2026 · issue area: Health Issues
$180,000
Spent on own lobbying
Nonprescription Drug Innovation Act (H.R.9774); dietary supplements; Generally Recognized as Safe (GRAS); Over the Counter Monograph User Fee Act (OMUFA); Generally Recognized as Safe and Effective (GRASE)…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing